| Medical and Health Sciences | Lifetime | 432 | US 234 | 99.98 |
| Environmental Science and Ecology | Lifetime | 871 | US 306 | 99.74 |
| Pharmacology | Lifetime | 6 | US 4 | 99.93 |
| Nutrition and Dietetics | Lifetime | 22 | US 11 | 99.88 |
| Oncology | Lifetime | 79 | US 43 | 99.86 |
| Health, Toxicology and Mutagenesis | Lifetime | 44 | US 15 | 99.81 |
| Pediatrics, Perinatology and Child Health | Lifetime | 207 | US 101 | 99.39 |
| Clinical Pharmacology | Lifetime | 402 | US 171 | 98.31 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 718 | US 382 | 97.54 |
| Clinical Biochemistry | Lifetime | 236 | US 109 | 95.82 |
| Biochemistry | Lifetime | 468 | US 217 | 93.04 |
| Dermatology | Lifetime | 940 | US 379 | 86.53 |
| Dermatology | 2021-2025 | 308 | US 108 | 82.22 |
| Health, Toxicology and Mutagenesis | 2021-2025 | 898 | US 229 | 71.46 |
| Heavy Metal Exposure and Toxicity | Lifetime | 2 | US 2 | 99.92 |
| Drug-Induced Hepatotoxicity and Protection | Lifetime | 3 | US 2 | 99.90 |
| Drug Transport and Resistance Mechanisms | Lifetime | 6 | US 4 | 99.88 |
| Trace Elements in Health | Lifetime | 5 | US 4 | 99.86 |
| Pharmacogenetics and Drug Metabolism | Lifetime | 7 | US 4 | 99.81 |
| Genomics, phytochemicals, and oxidative stress | Lifetime | 11 | US 5 | 99.69 |
| Pharmacological Effects and Toxicity Studies | Lifetime | 26 | US 9 | 99.75 |
| Pediatric Hepatobiliary Diseases and Treatments | Lifetime | 44 | US 23 | 99.57 |
| Pharmacological Effects of Medicinal Plants | Lifetime | 4 | US 1 | 99.60 |
| Metabolism and Genetic Disorders | Lifetime | 142 | US 62 | 99.23 |
| Neonatal Health and Biochemistry | Lifetime | 71 | US 41 | 98.89 |
| Liver Disease Diagnosis and Treatment | Lifetime | 414 | US 149 | 99.41 |
| Pesticide Exposure and Toxicity | Lifetime | 58 | US 27 | 98.91 |
| Glutathione Transferases and Polymorphisms | Lifetime | 39 | US 20 | 98.91 |
| Iron Metabolism and Disorders | Lifetime | 140 | US 64 | 98.75 |
| Pharmaceutical studies and practices | Lifetime | 154 | US 87 | 98.44 |
| Cannabis and Cannabinoid Research | Lifetime | 160 | US 77 | 98.31 |
| Heavy metals in environment | Lifetime | 343 | US 62 | 98.66 |
| Hormonal Regulation and Hypertension | Lifetime | 336 | US 146 | 98.37 |
| Pregnancy and Medication Impact | Lifetime | 193 | US 83 | 97.66 |
| Estrogen and related hormone effects | Lifetime | 786 | US 451 | 97.37 |
| Folate and B Vitamins Research | Lifetime | 477 | US 236 | 96.53 |
| Peroxisome Proliferator-Activated Receptors | Lifetime | 445 | US 216 | 97.06 |
| Thyroid Disorders and Treatments | Lifetime | 399 | US 151 | 97.25 |
| Effects and risks of endocrine disrupting chemicals | Lifetime | 623 | US 212 | 96.94 |
| Carcinogens and Genotoxicity Assessment | Lifetime | 736 | US 347 | 96.61 |
| Eicosanoids and Hypertension Pharmacology | Lifetime | 851 | US 411 | 95.62 |
| Immunotoxicology and immune responses | Lifetime | 88 | US 52 | 94.55 |
| Sulfur Compounds in Biology | Lifetime | 562 | US 172 | 93.82 |
| Ion Transport and Channel Regulation | Lifetime | 916 | US 428 | 93.56 |
| Aluminum toxicity and tolerance in plants and animals | Lifetime | 617 | US 108 | 92.00 |
| Agricultural safety and regulations | Lifetime | 199 | US 17 | 87.43 |
| Chemotherapy-induced organ toxicity mitigation | Lifetime | 354 | US 93 | 88.97 |
| Berberine and alkaloids research | Lifetime | 557 | US 78 | 85.26 |
| Nitrogen and Sulfur Effects on Brassica | Lifetime | 845 | US 156 | 83.48 |
| Paraquat toxicity studies and treatments | Lifetime | 740 | US 134 | 53.50 |
| Drug Transport and Resistance Mechanisms | 2021-2025 | 526 | US 128 | 81.33 |
| Pesticide Exposure and Toxicity | 2021-2025 | 329 | US 68 | 80.25 |
| Contact Dermatitis and Allergies | 2021-2025 | 369 | US 88 | 83.35 |
| Agricultural safety and regulations | 2021-2025 | 248 | US 18 | 65.03 |
| Animal testing and alternatives | 2021-2025 | 710 | US 229 | 46.91 |
| Medical Device Sterilization and Disinfection | 2021-2025 | 531 | US 155 | 28.45 |
| Chemical Safety and Risk Management | 2021-2025 | 259 | US 77 | 31.53 |
| Polymer Science and PVC | 2021-2025 | 445 | US 31 | 27.70 |
| Safe Handling of Antineoplastic Drugs | 2021-2025 | 342 | US 72 | 23.57 |